Quantum Genomics - Share From reverse s

OTCPK:QNNTF (France)   Share From reverse split
$ 0.10 0 (0%) 10:08 PM EST
At Loss
Enterprise V:
$ -3.14M
Volume:
-
Avg Vol (2M):
4.00K
Also Trade In:
Volume:
-
At Loss
Avg Vol (2M):
4.00K
PE Ratio PS Ratio PB Ratio Price-to-FCF Market Cap
Current and historical daily PE Ratio for Quantum Genomics ( ) from 2017 to May 09 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Quantum Genomics stock (QNNTF) PE ratio as of May 09 2024 is 0. More Details

Quantum Genomics (QNNTF) PE Ratio (TTM) Chart

To

Quantum Genomics (QNNTF) PE Ratio (TTM) Historical Data

Total 747
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 9
Quantum Genomics PE Ratio (TTM) Historical Data
Date PE Ratio (TTM) Data Date PE Ratio (TTM) Data
2024-05-09 At Loss 2024-03-06 At Loss
2024-05-08 At Loss 2024-03-05 At Loss
2024-05-07 At Loss 2024-03-04 At Loss
2024-05-06 At Loss 2024-03-01 At Loss
2024-05-03 At Loss 2024-02-29 At Loss
2024-05-02 At Loss 2024-02-28 At Loss
2024-05-01 At Loss 2024-02-27 At Loss
2024-04-30 At Loss 2024-02-26 At Loss
2024-04-29 At Loss 2024-02-23 At Loss
2024-04-26 At Loss 2024-02-22 At Loss
2024-04-25 At Loss 2024-02-21 At Loss
2024-04-24 At Loss 2024-02-20 At Loss
2024-04-23 At Loss 2024-02-16 At Loss
2024-04-22 At Loss 2024-02-15 At Loss
2024-04-19 At Loss 2024-02-14 At Loss
2024-04-18 At Loss 2024-02-13 At Loss
2024-04-17 At Loss 2024-02-12 At Loss
2024-04-16 At Loss 2024-02-09 At Loss
2024-04-15 At Loss 2024-02-08 At Loss
2024-04-12 At Loss 2024-02-07 At Loss
2024-04-11 At Loss 2024-02-06 At Loss
2024-04-10 At Loss 2024-02-05 At Loss
2024-04-09 At Loss 2024-02-02 At Loss
2024-04-08 At Loss 2024-02-01 At Loss
2024-04-05 At Loss 2024-01-31 At Loss
2024-04-04 At Loss 2024-01-30 At Loss
2024-04-03 At Loss 2024-01-29 At Loss
2024-04-02 At Loss 2024-01-26 At Loss
2024-04-01 At Loss 2024-01-25 At Loss
2024-03-28 At Loss 2024-01-24 At Loss
2024-03-27 At Loss 2024-01-23 At Loss
2024-03-26 At Loss 2024-01-22 At Loss
2024-03-25 At Loss 2024-01-19 At Loss
2024-03-22 At Loss 2024-01-18 At Loss
2024-03-21 At Loss 2024-01-17 At Loss
2024-03-20 At Loss 2024-01-16 At Loss
2024-03-19 At Loss 2024-01-12 At Loss
2024-03-18 At Loss 2024-01-11 At Loss
2024-03-15 At Loss 2024-01-10 At Loss
2024-03-14 At Loss 2024-01-09 At Loss
2024-03-13 At Loss 2024-01-08 At Loss
2024-03-12 At Loss 2024-01-05 At Loss
2024-03-11 At Loss 2024-01-04 At Loss
2024-03-08 At Loss 2024-01-03 At Loss
2024-03-07 At Loss 2024-01-02 At Loss

Quantum Genomics (QNNTF) PE Ratio (TTM) Comparison

Company Market Cap(Mil) PE Ratio (TTM)

Business Description

Business Description

Quantum Genomics
NAICS : 325412 SIC : 2834
ISIN : FR0011648971

Share Class Description:

QNNTF: Share From reverse split
Description
Quantum Genomics is a biopharmaceutical company engaged in developing new products for unmet needs in the field of cardiovascular diseases, high blood pressure, and heart failure. The company products include firibastat, QGC006, QGC011, and others.